ProSomnus® Announces Acceptance of Abstract at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference

Rhea-AI Summary

ProSomnus, Inc. (NASDAQ: OSA), a leader in precision medical devices for Obstructive Sleep Apnea (OSA), announced a significant development with an abstract on the efficacy of its Precision Oral Appliance Therapy (OAT) being accepted for presentation at the Sleep and Breathing 2023 Conference in Prague, scheduled for April 20-22, 2023.

Dr. Shouresh Charkhandeh will present the findings on April 20. ProSomnus’s FDA-cleared devices offer patient-specific solutions, demonstrating excellent efficacy and compliance compared to traditional treatments, including CPAP machines.

With over 200,000 devices delivered, ProSomnus’s products are widely prescribed, supported by positive clinical research outcomes, and are recognized by key health programs.

Positive

• Abstract on Precision OAT accepted at major conference, enhancing visibility.
• FDA-cleared devices have shown excellent efficacy and robust patient compliance.
• Over 200,000 devices delivered, indicating strong market acceptance.
• Recognized by Department of Defense and covered by major health insurance.

Negative

• None.

PLEASANTON, Calif., March 10, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that an abstract showcasing data from a study comparing the efficacy of Precision Oral Appliance Therapy (OAT) and traditional OAT has been accepted for a Thematic Poster Session at the European Respiratory Society (ERS) and European Sleep Research Society’s (ESRS) Sleep and Breathing 2023 Conference, being held from April 20-22 in Prague, Czech Republic.

Dr. Shouresh Charkhandeh, BMedSc, DDS, is scheduled to present the data in a session titled, “Pharmacological and non-pharmacological treatment and lifestyle interventions in sleep disordered breathing,” on Thursday, April 20 at 2:00 p.m. Central European Time/8:00 a.m. Eastern Time.

ProSomnus’s FDA-cleared, Precision OAT devices are a practical alternative to legacy oral devices and CPAP machines. In clinical studies, ProSomnus devices have demonstrated excellent efficacy and robust patient compliance relative to other treatment options. They reposition and stabilize the jaw during sleep, improving airflow through a patient's pharyngeal space. ProSomnus Precision OAT devices consist of maxillary and mandibular aligners that are precision-manufactured with twin-mated posts, and are digitally milled to be patient-specific. Prescribed advancements can be achieved by removing the current upper- or lower-device arch and inserting the next arch in the mandibular advancement series.

About ProSomnus
ProSomnus (NASDAQ: OSA) precision intraoral medical devices offer effective, economical, and patient-preferred treatment for patients suffering from Obstructive Sleep Apnea (OSA). ProSomnus is the first manufacturer of mass-customized Precision Oral Appliance Therapy (OAT) devices to treat OSA, which affects over 74 million people in North America and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus’s patented, FDA-cleared devices are a less invasive and more comfortable alternative to Continuous Positive Airway Pressure (CPAP) therapy, and lead to effective and patient-preferred outcomes. A growing body of research, including studies published by the Journal of Clinical Sleep Medicine and Military Medicine, suggests ProSomnus’s Precision OAT devices are an effective treatment for mild to moderate OSA. Additional clinical research has shown that ProSomnus’s Precision OAT devices mitigate many of the side effects associated with alternative treatments and improve economics for payers and providers. With more than 200,000 devices delivered, ProSomnus’s devices are the most prescribed Precision OAT in the U.S. ProSomnus’s FDA-cleared devices are authorized by the Department of Defense and the U.S. Army, and are often covered by medical insurance, Medicare, and social health programs in key international markets. To learn more, visit www.ProSomnus.com.

Investor Contact
Mike Cavanaugh
ICR Westwicke
Phone: +1.617.877.9641
Email: Mike.Cavanaugh@westwicke.com

Media Contact
Elizabeth Coleman
ICR Westwicke
Phone: +1.203.682.4783
Email: Elizabeth.Coleman@westwicke.com

FAQ

What is ProSomnus's recent announcement regarding OSA?

ProSomnus announced that its research on Precision Oral Appliance Therapy (OAT) has been accepted for presentation at the Sleep and Breathing 2023 Conference.

When will ProSomnus present at the Sleep and Breathing 2023 Conference?

ProSomnus will present on April 20, 2023, at the Sleep and Breathing 2023 Conference in Prague.

What is the significance of the Precision OAT devices by ProSomnus?

ProSomnus's Precision OAT devices provide a patient-specific alternative to traditional OSA treatments, demonstrating high efficacy and compliance.

How many Precision OAT devices has ProSomnus delivered?

ProSomnus has delivered over 200,000 Precision OAT devices, making them the most prescribed in the U.S.